Impact Investing in Cardiovascular Disease

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Getting Treatments to Patients

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

Diversified Portfolio Across Technologies

Broadview’s mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.

OUR PORTFOLIO

View All

PRESS

May 27, 2026
Cardiosense Receives FDA De Novo Classification for Novel Cardiac Technology Designed to Improve Care for Patients with Heart Failure
Read More
May 21, 2026
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Read More
May 20, 2026
HAYA Therapeutics Announces First Cohort Dosed in Phase 1 Clinical Trial of HTX-001
Read More
May 14, 2026
Nyra Medical to Highlight First-in-Human Clinical Insights Through Three Presentations at EuroPCR
Read More
View All